Exploring the NK cell platform for cancer immunotherapy

By Jacob A. Myers, Jeffrey S. Miller. Nature Reviews Clinical Oncology, 2020

1,050 citations recorded by the source corpus.

Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell-mediated immunotherapy emerged as a safe and effective treatment approach for patients with advanced-stage leukaemia. Subsequently, the field of NK cell-based cancer therapy has grown exponentially and currently constitutes a major area of immunotherapy innovation. In general, the development of NK cell-directed therapies has two main focal points: optimizing the source of therapeutic NK cells for adoptive transfer and enhancing NK cell cytotoxicity and persistence in vivo. A wide variety of sources of therapeutic NK cells are currently being tested clinically, including haploidentical NK cells, umbilical cord blood NK cells, stem cell-derived NK cells, NK cell lines, adaptive NK cells, cytokine-induced memory-like NK cells and chimeric antigen receptor NK cells. A plethora of methods to augment the cytotoxicity and longevity of NK cells are also under clinical investigation, including cytokine-based agents, NK cell-engager molecules and immune-checkpoint inhibitors. In this Review, we highlight the variety of ways in which diverse NK cell products and their auxiliary therapeutics are being leveraged to target human cancers. We also identify future avenues for NK cell therapy research. Natural killer (NK) cells have an innate potential to kill cancerous cells and considerable effort is being focused on innovative approaches to leverage these cells for cancer therapy. Herein, the authors discuss the variety of NK cell-based therapies that are being developed for the treatment of diverse cancers and identify future avenues for NK cell therapy research. Natural killer (NK) cell-based therapies are emerging as safe and efficacious treatments for some cancers. Generally, the two main considerations relating to NK cell therapies are the choice of NK cell source and the method of in vivo enhancement of NK cell function; determining approaches to optimize both of these aspects is of high clinical interest. Therapeutic NK cells include haploidentical NK cells, chimeric antigen receptor NK cells, stem cell-derived NK cells, umbilical cord blood NK cells, NK cell lines, adaptive NK cells and cytokine-induced memory-like NK cells. Auxiliary methods for enhancing the therapeutic activity of NK cells in vivo include cytokine-based agents, NK cell-engager molecules (such as TriKEs, ROCK engagers, NKCEs and TriNKETs) and immune-checkpoint inhibitors. Potential advantages that NK cell therapies have over T cell therapies include more manageable safety profiles and fewer graft restrictions (for example, no requirement for autologous cells, providing opportunities for off-the-shelf products). NK cell therapies remain subject to important immunosuppressive barriers in the tumour microenvironment; the future success of these therapies will require a better understanding of how these suppressive factors operate and how they can be overcome.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/c5099f30bb4c07228a7044762e58752667e5d8ca